Prestige Consumer Healthcare (NYSE:PBH) Reaches New 52-Week High – Should You Buy?

Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) reached a new 52-week high on Tuesday . The company traded as high as $82.56 and last traded at $82.27, with a volume of 8579 shares trading hands. The stock had previously closed at $81.75.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on PBH. DA Davidson reiterated a “buy” rating and set a $95.00 price target on shares of Prestige Consumer Healthcare in a research report on Monday. Jefferies Financial Group reiterated a “hold” rating and set a $76.00 target price (up from $70.00) on shares of Prestige Consumer Healthcare in a research report on Tuesday, September 24th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $94.20.

Prestige Consumer Healthcare Price Performance

The firm has a market capitalization of $4.07 billion, a price-to-earnings ratio of 20.03, a price-to-earnings-growth ratio of 2.30 and a beta of 0.47. The company has a quick ratio of 2.10, a current ratio of 3.56 and a debt-to-equity ratio of 0.61. The company’s fifty day moving average is $72.84 and its two-hundred day moving average is $70.00.

Prestige Consumer Healthcare (NYSE:PBH) last issued its earnings results on Thursday, November 7th. The company reported $1.09 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.09. Prestige Consumer Healthcare had a return on equity of 12.23% and a net margin of 18.54%. The firm had revenue of $283.79 million for the quarter, compared to analysts’ expectations of $282.09 million. During the same quarter last year, the business earned $1.07 earnings per share. The company’s revenue was down .9% compared to the same quarter last year. Equities research analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.45 earnings per share for the current fiscal year.

Institutional Trading of Prestige Consumer Healthcare

Several hedge funds have recently added to or reduced their stakes in PBH. SG Americas Securities LLC acquired a new stake in shares of Prestige Consumer Healthcare in the 1st quarter valued at approximately $218,000. Swiss National Bank lifted its position in Prestige Consumer Healthcare by 0.3% during the first quarter. Swiss National Bank now owns 97,900 shares of the company’s stock worth $7,104,000 after purchasing an additional 300 shares during the period. Headlands Technologies LLC acquired a new stake in shares of Prestige Consumer Healthcare during the 1st quarter worth approximately $55,000. ProShare Advisors LLC boosted its holdings in shares of Prestige Consumer Healthcare by 7.4% in the 1st quarter. ProShare Advisors LLC now owns 10,042 shares of the company’s stock valued at $729,000 after purchasing an additional 691 shares in the last quarter. Finally, Entropy Technologies LP bought a new position in Prestige Consumer Healthcare in the first quarter valued at about $383,000. Institutional investors and hedge funds own 99.95% of the company’s stock.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.